A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Sponsor: |
National Cancer Institute |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR4308 |
U.S. Govt. ID: |
NCT03148275 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to determine the safety and effectiveness of the study drug in patients with Metastatic Epithelioid Hemangioendothelioma (EHE). The study drug is called trametinib. Trametinib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size. Trametinib has already been FDA-approved to treat other cancer. There will be up to 27 people taking part in this study.
This study is closed
Investigator
Gary Schwartz, MD
Are you 18 years or older? |
Yes |
No |
Have you been diagnosed with Epithelioid Hemangioendothelioma (EHE)? |
Yes |
No |